Trexquant Investment LP lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 52.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,160 shares of the biopharmaceutical company’s stock after selling 22,240 shares during the period. Trexquant Investment LP’s holdings in Amicus Therapeutics were worth $304,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in FOLD. Teachers Advisors LLC raised its holdings in shares of Amicus Therapeutics by 5.4% in the first quarter. Teachers Advisors LLC now owns 253,499 shares of the biopharmaceutical company’s stock valued at $1,807,000 after purchasing an additional 12,936 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Amicus Therapeutics by 25.3% in the first quarter. Dimensional Fund Advisors LP now owns 360,148 shares of the biopharmaceutical company’s stock valued at $2,568,000 after purchasing an additional 72,674 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Amicus Therapeutics by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 562,951 shares of the biopharmaceutical company’s stock valued at $4,014,000 after purchasing an additional 30,177 shares during the last quarter. Credit Suisse AG raised its holdings in shares of Amicus Therapeutics by 58.9% in the first quarter. Credit Suisse AG now owns 293,835 shares of the biopharmaceutical company’s stock valued at $2,095,000 after purchasing an additional 108,906 shares during the last quarter. Finally, Aperio Group LLC raised its holdings in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares during the last quarter.

Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $12.51 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics, Inc. has a 1 year low of $4.41 and a 1 year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. Amicus Therapeutics’s quarterly revenue was up 419.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.33) EPS. research analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. Goldman Sachs Group reiterated a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. Chardan Capital reiterated a “buy” rating and issued a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $17.81.

In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the transaction, the insider now owns 69,184 shares in the company, valued at $940,210.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Crowley sold 449,295 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the transaction, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,455,760.59. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 633,224 shares of company stock valued at $9,091,953. 3.40% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Trexquant Investment LP Has $304,000 Stake in Amicus Therapeutics, Inc. (FOLD)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/06/trexquant-investment-lp-has-304000-stake-in-amicus-therapeutics-inc-fold.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.